<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427710</url>
  </required_header>
  <id_info>
    <org_study_id>CiVi-001</org_study_id>
    <nct_id>NCT03427710</nct_id>
  </id_info>
  <brief_title>A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level</brief_title>
  <official_title>A Placebo-controlled, Single Blind, Randomised, Phase I, First In Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered CiVi007 in Subjects With an Elevated LDL C Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Civi Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Civi Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess pharmacokinetics, dynamics, safety and&#xD;
      tolerability of CiVi007 following single and multiple subcutaneous doses in subjects,&#xD;
      including those on statin therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Actual">August 18, 2020</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adaptive design allowing modifications in single and multidose arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>Maximum post dose within 8 weeks</time_frame>
    <description>% LDL-C reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of CiVi007</measure>
    <time_frame>8 weeks</time_frame>
    <description>Pharmacokinetic Outcome Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCSK9 level</measure>
    <time_frame>Maximum post dose within 8 weeks</time_frame>
    <description>maximal % reduction in the level of circulating PCSK9</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CiVi007 dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CiVi007 dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CiVi007 dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CiVi007 dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CiVi007 dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group response from placebo subsets of dosing cohorts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CiVi007</intervention_name>
    <description>cholesterol lowering drug</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_label>Cohort A5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo to CiVi007</description>
    <arm_group_label>Combined placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, of any race, with fasting LDL C &gt;2.6 mmol/L (100 mg/dL) and fasting&#xD;
             serum triglycerides &lt;4.52 mmol/L (400 mg/dL)&#xD;
&#xD;
          -  haematology and clinical chemistry without clinically significant abnormal values&#xD;
&#xD;
          -  Normal renal and hepatic function&#xD;
&#xD;
          -  Women must not be pregnant, lactating or of child bearing potential&#xD;
&#xD;
          -  Men must be willing to use appropriate contraception during the study&#xD;
&#xD;
          -  Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any uncontrolled or serious disease, or any medical or surgical condition&#xD;
&#xD;
          -  History or presence of coronary heart disease, peripheral artery disease, or&#xD;
             cerebrovascular disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Insulin dependent diabetes mellitus&#xD;
&#xD;
          -  Secondary dyslipidemia&#xD;
&#xD;
          -  History of renal or hepatic diseases, acquired immune deficiency syndrome, positive&#xD;
             human immunodeficiency virus test and/or history of viral hepatitis B or C&#xD;
&#xD;
          -  History of cancer within 5 years&#xD;
&#xD;
          -  History of high alcohol consumption or positive alcohol breath test or urinary test&#xD;
             for drugs of abuse&#xD;
&#xD;
          -  Participation in another clinical study within 3 months prior to screening or&#xD;
             participation in another study&#xD;
&#xD;
          -  Use of treatment (e.g. antibody) towards PCSK9&#xD;
&#xD;
          -  History of multiple drug allergies or intolerance to subcutaneous injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Clinic</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

